PHCP, LLC (PHCP) provides top-tier investment banking capabilities exclusively to biotech, biopharma and healthcare companies across all stages of development
OUR STORY
Helping Clients Unlock Shareholder Value
A wholly-owned subsidiary of Paragon Biosciences, PHCP was founded in 2019 to work closely with Paragon company management teams and boards to achieve their strategic and financial objectives. We have managed narrow and broad M&A and capital raise processes and are intensely focused on delivering outstanding outcomes and value generating transactions.
PHCP Clients
At PHCP, we collaborate closely with founders, executives, and board members to provide comprehensive strategic and financial advice through every phase of their company’s development. To understand the type of companies and sectors we tend to work with, take a look at some of our current and past engagements.
Develops and commercializes innovative therapies for patients with rare neurological diseases.
Late-stage development for a new class of drug for patients with Tourette syndrome and other neurological disorders.
Uses generative AI to design novel protein therapeutics for autoimmune diseases with high unmet needs.
A regenerative medicine company conducting a registrational Phase 3 trial for patients with dystrophic epidermolysis bullosa.
Develops regenerative medicines that restore function. Its therapeutic platform chemically reprograms cells to replace those lost to degenerative disease.